Morgan Stanley (NYSE:MS) analyst Ricky Goldwasser maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Monday, setting a price target of $115, which is approximately 26.55% above the present share price of $90.87.
Goldwasser expects CVS Health Corp to post earnings per share (EPS) of $1.21 for the fourth quarter of 2021.
The current consensus among 17 TipRanks analysts is for a Strong Buy rating of shares in CVS Health, with an average price target of $109.06.
The analysts price targets range from a high of $115 to a low of $100.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $73.79 billion and a net profit of $3.49 billion. The company's market cap is $119.95 billion.
According to TipRanks.com, Morgan Stanley analyst Ricky Goldwasser is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 14.5% and a 65.47% success rate.
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna (NYSE:AET), a health insurance provider, among many other brands.